Table 3 Multivariate logistic regression models of risk factors for MTX-related difficulties
Potential risk factors | MTX problems | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Feel sick before taking MTX | Feel sick after taking MTX | Vomit after taking MTX | Anxious about blood tests | Anxious about injections | |||||||
n | Unadjusted Exp(β) (95% CI) | Adjusted Exp (β) † (95% CI) | Unadjusted Exp(β) (95% CI) | Adjusted Exp (β) † (95% CI) | Unadjusted Exp(β) (95% CI) | Adjusted Exp (β) † (95% CI) | Unadjusted Exp(β) (95% CI) | Adjusted Exp (β) † (95% CI) | Unadjusted Exp(β) (95% CI) | Adjusted Exp (β) † (95% CI) | |
Age | 171 | 1.10 (1.01–1.19) | 1.06 (0.92–1.22) | 1.15 (1.06–1.24) | 1.11 (0.98–1.25) | 1.06 (0.97–1.17) | 1.07 (0.92–1.24) | 0.82 (0.75–0.90) | 0.76 (0.65-0.89) | 0.85 (0.79–0.93) | 0.83 (0.73–0.95) |
Sex | |||||||||||
Male | 48 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Female | 123 | 0.56 | 0.89 | 1.06 | 1.38 | 0.52 | 0.48 | 1.18 | 0.87 | 0.79 | 0.78 |
(0.28–1.15) | (0.37–2.16) | (0.54–2.08) | (0.62–3.09) | (0.24–1.16) | (0.19–1.25) | (0.58–2.42) | (0.35-2.18) | (0.40–1.55) | (0.32–1.88) | ||
MTX current route | |||||||||||
Oral | 71 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Subcutaneous | 100 | 2.51 | 2.33 | 1.39 | 1.50 | 3.21 | 3.75 | 1.25 | 0.79 | 2.40 | 2.31 |
(1.21–5.19) | (0.96–5.66) | (0.75–2.58) | (0.69–3.26) | (1.31–7.89) | (1.28–11.06) | (0.66–2.40) | (0.34-1.87) | (1.27–4.54) | (1.02–5.22) | ||
MTX current dose (mg) | 171 | 1.10 | 1.06 | 1.11 | 1.06 | 1.05 | 0.98 | 0.95 | 1.10 | 0.96 | 1.03 |
(1.02–1.19) | (0.95–1.19) | (1.04–1.20) | (0.96–1.17) | (0.97–1.14) | (0.88–1.10) | (0.88–1.02) | (0.97-1.25) | (0.89–1.02) | (0.93–1.15) | ||
Duration of MTX use in months | 168 | 1.02 | 1.01 | 1.01 | 1.01 | 1.02 | 1.01 | 0.98 | 0.996 | 0.995 | 1.00 |
(1.01 - 1.03) | (0.99-1.03) | (1.00- 1.03) | (0.99-1.02) | (1.00 -1.03) | (0.99-1.03) | (0.97-0.997) | (0.98-1.01) | (0.98 - 1.01) | (0.98 - 1.01) | ||
Taking folic acid | |||||||||||
No | 24 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Yes | 124 | 0.41 | 0.55 | 0.48 | 0.68 | 0.41 | 0.57 | 1.02 | 0.98 | 0.76 | 0.42 |
(0.17 – 1.01) | (0.19 – 1.58) | (0.20 – 1.17) | (0.25 – 1.85) | (0.16 – 1.08) | (0.18 – 1.76) | (0.41 – 2.59) | (0.32 - 3.03) | (0.27 – 1.60) | (0.14 – 1.25) | ||
Current disease severity: | |||||||||||
No. active joints | 158 | 1.24 | 1.29 | 1.07 | 1.09 | 1.07 | 0.91 | 1.20 | 1.15 | 1.23 | 1.40 |
(1.06 – 1.44) | (1.05 – 1.60) | (0.92 – 1.23) | (0.91 – 1.30) | (0.91 – 1.25) | (0.74 – 1.13) | (0.97 – 1.29) | (0.95 - 1.40) | (1.03 – 1.46) | (1.09 – 1.79) | ||
No. limited joints | 155 | 1.09 | 1.01 | 1.01 | 0.95 | 1.09 | 1.04 | 0.97 | 0.97 | 0.98 | 0.93 |
(0.99 – 1.20) | (0.91 – 1.12) | (0.92 – 1.10) | (0.85 – 1.06) | (0.99 – 1.21) | (0.92 – 1.17) | (0.88 – 1.08) | (0.85 - 1.10) | (0.90 – 1.07) | (0.82 – 1.06) | ||